Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221117829> ?p ?o ?g. }
- W4221117829 endingPage "1609" @default.
- W4221117829 startingPage "1609" @default.
- W4221117829 abstract "The CDH1 gene, encoding the cell adhesion protein E-cadherin, is one of the most frequently mutated genes in gastric cancer and inactivating germline CDH1 mutations are responsible for the cancer syndrome hereditary diffuse gastric cancer (HDGC). CDH1-deficient gastric cancers exhibit high AKT serine/threonine kinase 3 (AKT3) expression, but specific drugs against this AKT isoform are not available. We therefore used two publicly available datasets to identify AKT3-associated genes which could be used to indirectly target AKT3. Reactome analysis identified an enrichment of extracellular matrix remodelling genes in AKT3-high gastric cancers. Of the 51 genes that were significantly correlated with AKT3 (but not AKT1), discoidin domain receptor tyrosine kinase 2 (DDR2) showed the strongest positive association. Treatment of isogenic human cells and mouse gastric and mammary organoids with dasatinib, a small molecule inhibitor of multiple kinases including SRC, BCR-ABL and DDR2, preferentially slowed the growth and induced apoptosis of E-cadherin-deficient cells. Dasatinib treatment also preferentially slowed the growth of gastric and mammary organoids harbouring both Cdh1 and Tp53 mutations. In organoid models, dasatinib treatment was associated with decreased phosphorylation of total AKT, with a stronger effect seen in Cdh1-deficient organoids. Treatment with combinations of dasatinib and an inhibitor of AKT, MK2206, enhanced the effect of dasatinib in breast MCF10A cells. In conclusion, targeting the DDR2-SRC-AKT3 axis with dasatinib represents a promising approach for the chemoprevention and chemotherapy of gastric and breast cancers lacking E-cadherin." @default.
- W4221117829 created "2022-04-03" @default.
- W4221117829 creator A5012739492 @default.
- W4221117829 creator A5020042051 @default.
- W4221117829 creator A5033112608 @default.
- W4221117829 creator A5034970322 @default.
- W4221117829 creator A5042222507 @default.
- W4221117829 creator A5063087649 @default.
- W4221117829 creator A5088615939 @default.
- W4221117829 creator A5088667864 @default.
- W4221117829 date "2022-03-22" @default.
- W4221117829 modified "2023-10-14" @default.
- W4221117829 title "E-Cadherin-Deficient Cells Are Sensitive to the Multikinase Inhibitor Dasatinib" @default.
- W4221117829 cites W14778716 @default.
- W4221117829 cites W1592729189 @default.
- W4221117829 cites W1651458958 @default.
- W4221117829 cites W1908864745 @default.
- W4221117829 cites W1921454671 @default.
- W4221117829 cites W1940799857 @default.
- W4221117829 cites W1986139301 @default.
- W4221117829 cites W1989277387 @default.
- W4221117829 cites W1996776596 @default.
- W4221117829 cites W2011852093 @default.
- W4221117829 cites W2012117840 @default.
- W4221117829 cites W2014706039 @default.
- W4221117829 cites W2023461645 @default.
- W4221117829 cites W2031388170 @default.
- W4221117829 cites W2038001106 @default.
- W4221117829 cites W2039604857 @default.
- W4221117829 cites W2049397238 @default.
- W4221117829 cites W2054531472 @default.
- W4221117829 cites W2067365317 @default.
- W4221117829 cites W2068187102 @default.
- W4221117829 cites W2072470959 @default.
- W4221117829 cites W2087367170 @default.
- W4221117829 cites W2088875220 @default.
- W4221117829 cites W2090551359 @default.
- W4221117829 cites W2097269634 @default.
- W4221117829 cites W2100181504 @default.
- W4221117829 cites W2102035722 @default.
- W4221117829 cites W2103562758 @default.
- W4221117829 cites W2105956673 @default.
- W4221117829 cites W2107060225 @default.
- W4221117829 cites W2120865735 @default.
- W4221117829 cites W2126547130 @default.
- W4221117829 cites W2131916131 @default.
- W4221117829 cites W2135630508 @default.
- W4221117829 cites W2136368542 @default.
- W4221117829 cites W2137526110 @default.
- W4221117829 cites W2141244447 @default.
- W4221117829 cites W2145449209 @default.
- W4221117829 cites W2153076514 @default.
- W4221117829 cites W2154284302 @default.
- W4221117829 cites W2163957613 @default.
- W4221117829 cites W2165299947 @default.
- W4221117829 cites W2169100979 @default.
- W4221117829 cites W2184894459 @default.
- W4221117829 cites W2209181844 @default.
- W4221117829 cites W2302918002 @default.
- W4221117829 cites W2310968520 @default.
- W4221117829 cites W2330903611 @default.
- W4221117829 cites W2339267986 @default.
- W4221117829 cites W2345091078 @default.
- W4221117829 cites W2409709394 @default.
- W4221117829 cites W2611847235 @default.
- W4221117829 cites W2884002072 @default.
- W4221117829 cites W2886017545 @default.
- W4221117829 cites W2893255028 @default.
- W4221117829 cites W2938774982 @default.
- W4221117829 cites W2953590029 @default.
- W4221117829 cites W2959016616 @default.
- W4221117829 cites W2959623928 @default.
- W4221117829 cites W2972775569 @default.
- W4221117829 cites W2980681649 @default.
- W4221117829 cites W2990256362 @default.
- W4221117829 cites W3003924738 @default.
- W4221117829 cites W3012727287 @default.
- W4221117829 cites W3033875119 @default.
- W4221117829 cites W3047025380 @default.
- W4221117829 cites W3090399818 @default.
- W4221117829 cites W3108444342 @default.
- W4221117829 cites W3118931304 @default.
- W4221117829 cites W3130651220 @default.
- W4221117829 cites W3138636407 @default.
- W4221117829 cites W3141608077 @default.
- W4221117829 cites W3152862311 @default.
- W4221117829 cites W3174076261 @default.
- W4221117829 cites W3186991779 @default.
- W4221117829 cites W3209937574 @default.
- W4221117829 cites W3210262196 @default.
- W4221117829 cites W3214431145 @default.
- W4221117829 cites W4200018258 @default.
- W4221117829 cites W4200255951 @default.
- W4221117829 cites W4205493700 @default.
- W4221117829 cites W4231254854 @default.
- W4221117829 cites W97768830 @default.
- W4221117829 doi "https://doi.org/10.3390/cancers14071609" @default.
- W4221117829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35406381" @default.